- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02887352
French Adaptation of the California Card Sorting Task (CCST) in Multiple Sclerosis (E3C-DIFSEP)
June 11, 2021 updated by: Fondation Ophtalmologique Adolphe de Rothschild
French Adaptation of the CCST (California Card Sorting Task). Comparison of 3 Packages to CCST With Multiple Sclerosis (MS) Patients
Cognitive impairment affects up to 65% of multiple sclerosis (MS) subjects, especially executive functions.
The California Card Sorting Task (CCST) assesses specific components of problem-solving ability.
There is currently no French version of this test.
Reims neurological department in collaboration with Rothschild Foundation has developed a French adaptation of CCST.
This version includes three cards packages with two alternate forms to control practice effects (test-retest).
In order to assess "test-retest reliability" we have to verify the comparability of the three cards packages within one session in MS patients.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Actual)
48
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Paris, France, 75019
- Fondation Ophtalmologique Adolphe de Rothschild
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
multiple sclerosis patients
Description
Inclusion Criteria:
- Multiple Sclerosis patients
- age > 18 years old
Exclusion Criteria:
- Montreal Cognitive Assessment (MOCA) ≤20
- psychiatric disease
- no proficiency in the French language
- opposition to participate in the study
- no medical insurance coverage
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Other
- Time Perspectives: Cross-Sectional
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
CCST Test score
Time Frame: baseline
|
comparison of the scores of the three versions of the test
|
baseline
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Director: Anne-Claire VIRET, Fondation OPH A de Rothschild
- Principal Investigator: Olivier GOUT, MD, Fondation OPH A de Rothschild
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 1, 2014
Primary Completion (Actual)
January 1, 2020
Study Completion (Actual)
January 1, 2020
Study Registration Dates
First Submitted
August 25, 2016
First Submitted That Met QC Criteria
August 29, 2016
First Posted (Estimate)
September 2, 2016
Study Record Updates
Last Update Posted (Actual)
June 14, 2021
Last Update Submitted That Met QC Criteria
June 11, 2021
Last Verified
June 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- OGT_2014-1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
Cabaletta BioNot yet recruitingProgressive Multiple Sclerosis | Multiple Sclerosis | Multiple Sclerosis (Relapsing Remitting) | Relapsing Multiple Sclerosis (RMS) | Progressive Multiple Sclerosis (PMS) | Multiple Sclerosis (MS) - Relapsing-remitting | Multiple Sclerosis - Relapsing Remitting
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsActive, not recruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
Novartis PharmaceuticalsCompletedRelapsing-remitting Multiple Sclerosis | Active Secondary Progressive Multiple SclerosisJapan
-
Banc de Sang i TeixitsVall d'Hebron Research Institute (VHIR)CompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisSpain
-
BiogenElan PharmaceuticalsCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
Clinical Trials on assessment of problem-solving ability
-
University Hospital, MontpellierWithdrawn
-
University of WashingtonNational Institute of Mental Health (NIMH)CompletedDepressionUnited States
-
Istanbul UniversityCompleted
-
University of OttawaOttawa Hospital Research InstituteActive, not recruiting
-
Washington University School of MedicineNurses for Newborns FoundationCompletedPost-partum DepressionUnited States
-
VA Office of Research and DevelopmentCompletedDepression | AnxietyUnited States
-
University of PittsburghNational Institute of Mental Health (NIMH)CompletedMild Cognitive ImpairmentUnited States
-
VA Office of Research and DevelopmentCompleted
-
University of SheffieldUniversity of ManchesterCompleted
-
Children's Hospital Medical Center, CincinnatiPatient-Centered Outcomes Research Institute; Children's Hospital Colorado; Nationwide... and other collaboratorsCompletedWounds and Injuries | Brain Injuries | Craniocerebral Trauma | Trauma, Nervous System | Brain Concussion | Head Injuries, Closed | Head Injury | Brain Edema | Disorders of Environmental Origin | Brain Hemorrhage, Traumatic | Subdural Hematoma | Epidural Hematoma | Intracranial Edema | Tbi | Cortical ContusionUnited States